170 related articles for article (PubMed ID: 20826257)
1. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment.
Cadeddu C; Piras A; Mantovani G; Deidda M; Dessì M; Madeddu C; Massa E; Mercuro G
Am Heart J; 2010 Sep; 160(3):487.e1-7. PubMed ID: 20826257
[TBL] [Abstract][Full Text] [Related]
2. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mercuro G; Cadeddu C; Piras A; Dessì M; Madeddu C; Deidda M; Serpe R; Massa E; Mantovani G
Oncologist; 2007 Sep; 12(9):1124-33. PubMed ID: 17914082
[TBL] [Abstract][Full Text] [Related]
3. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction.
Dessì M; Piras A; Madeddu C; Cadeddu C; Deidda M; Massa E; Antoni G; Mantovani G; Mercuro G
Exp Ther Med; 2011 Sep; 2(5):1003-1009. PubMed ID: 22977612
[TBL] [Abstract][Full Text] [Related]
4. Effect of telmisartan in limiting the cardiotoxic effect of daunorubicin in rats.
Arozal W; Watanabe K; Veeraveedu PT; Thandavarayan RA; Harima M; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
J Pharm Pharmacol; 2010 Dec; 62(12):1776-83. PubMed ID: 21054405
[TBL] [Abstract][Full Text] [Related]
5. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers.
Mantovani G; Madeddu C; Cadeddu C; Dessì M; Piras A; Massa E; Serpe R; Antoni G; Mercuro G
Oncologist; 2008 Dec; 13(12):1296-305. PubMed ID: 19060235
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity.
Ibrahim MA; Ashour OM; Ibrahim YF; El-Bitar HI; Gomaa W; Abdel-Rahim SR
Pharmacol Res; 2009 Nov; 60(5):373-81. PubMed ID: 19467331
[TBL] [Abstract][Full Text] [Related]
7. Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker.
Shao J; Nangaku M; Inagi R; Kato H; Miyata T; Matsusaka T; Noiri E; Fujita T
J Hypertens; 2007 Aug; 25(8):1643-9. PubMed ID: 17620961
[TBL] [Abstract][Full Text] [Related]
8. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan.
Knorr M; Hausding M; Kröller-Schuhmacher S; Steven S; Oelze M; Heeren T; Scholz A; Gori T; Wenzel P; Schulz E; Daiber A; Münzel T
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2223-31. PubMed ID: 21757654
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer.
Zhang H; Shen WS; Gao CH; Deng LC; Shen D
Drugs R D; 2012 Jun; 12(2):101-6. PubMed ID: 22770377
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
Sanchez RA; Masnatta LD; Pesiney C; Fischer P; Ramirez AJ
J Hypertens; 2008 Dec; 26(12):2393-8. PubMed ID: 19008718
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats.
Hasegawa G; Fukui M; Hosoda H; Asano M; Harusato I; Tanaka M; Shiraishi E; Senmaru T; Sakabe K; Yamasaki M; Kitawaki J; Fujinami A; Ohta M; Obayashi H; Nakamura N
Eur J Pharmacol; 2009 Mar; 605(1-3):164-9. PubMed ID: 19171132
[TBL] [Abstract][Full Text] [Related]
12. Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate.
Dessì M; Madeddu C; Piras A; Cadeddu C; Antoni G; Mercuro G; Mantovani G
Springerplus; 2013 Dec; 2(1):198. PubMed ID: 23741643
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.
Sukumaran V; Watanabe K; Veeraveedu PT; Ma M; Gurusamy N; Rajavel V; Suzuki K; Yamaguchi K; Kodama M; Aizawa Y
Eur J Pharmacol; 2011 Feb; 652(1-3):126-35. PubMed ID: 21115000
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of telmisartan on left ventricular structure and function in patients with hypertension determined by two-dimensional strain imaging.
Mizuguchi Y; Oishi Y; Miyoshi H; Iuchi A; Nagase N; Oki T
J Hypertens; 2009 Sep; 27(9):1892-9. PubMed ID: 19506525
[TBL] [Abstract][Full Text] [Related]
15. Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage.
Jung KH; Chu K; Lee ST; Kim SJ; Song EC; Kim EH; Park DK; Sinn DI; Kim JM; Kim M; Roh JK
J Pharmacol Exp Ther; 2007 Sep; 322(3):1051-8. PubMed ID: 17538008
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Rinaldi B; Di Filippo C; Capuano A; Donniacuo M; Sodano L; Ferraraccio F; Rossi F; D'Amico M
Diabetes Obes Metab; 2012 Apr; 14(4):320-8. PubMed ID: 22050607
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan prevents the progression of renal injury in daunorubicin rats with the alteration of angiotensin II and endothelin-1 receptor expression associated with its PPAR-γ agonist actions.
Arozal W; Watanabe K; Veeraveedu PT; Ma M; Thandavarayan RA; Sukumaran V; Suzuki K; Kodama M; Aizawa Y
Toxicology; 2011 Jan; 279(1-3):91-9. PubMed ID: 20888384
[TBL] [Abstract][Full Text] [Related]
18. Telmisartan ameliorates germ cell toxicity in the STZ-induced diabetic rat: studies on possible molecular mechanisms.
Kushwaha S; Jena GB
Mutat Res; 2013 Jul; 755(1):11-23. PubMed ID: 23648321
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II type 1 receptor blocker telmisartan suppresses superoxide production and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Takaya T; Kawashima S; Shinohara M; Yamashita T; Toh R; Sasaki N; Inoue N; Hirata K; Yokoyama M
Atherosclerosis; 2006 Jun; 186(2):402-10. PubMed ID: 16157344
[TBL] [Abstract][Full Text] [Related]
20. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice.
Iwanami J; Mogi M; Tsukuda K; Min LJ; Sakata A; Jing F; Iwai M; Horiuchi M
J Hypertens; 2010 Aug; 28(8):1730-7. PubMed ID: 20498620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
